Dr. Ian Kovacs of PAREXEL International explains why ccompanies need to consider integrated approaches to risk management, ensuring that such activities commence early in clinical development.
Dr. Donald A. Wellings and Andrew Gallagher of Spheritech analyse a new novel biopolymer that has been developed, which has found many applications, especially in the formation of self-assembled macroporous biodegradable constructs specifically designed to support 3D cell culture.
Jo Parrish and Rachel Griffith at SWHR look into how cervical cancer begins in the cervix and gradually grows more invasive. One out of every 145 women has cervical cancer, yet cervical cancer is the most preventable cancer and the only one that can realistically be eradicated in our lifetime. This is a fact supported by science and innovation.
Dr. Charlotte Dyring, Dr. Wian de Jongh at ExpreS2ion Biotechnologies and Dr. Ali Salanti at the university of Copenhagen explain why development and optimisation of alternatives, such as stable insect cell-based platforms, remains of interest for the advancement of scientific and medical research.
Grzegorz Garbacz at the University of Greifswald, Werner Weitschies at University of Greifswald, and Sandra Klein at the University of Greifswald investigate how developing predictive in vitro test systems for solid oral dosage forms which are capable of a realistic simulation of gastrointestinal transit conditions is still a challenge.
Jaypreet Dhillon from IPI speaks with Jean Stéphenne at GSK Biologicals about the milestones that marked the cluster from its very beginning and their vision of the future.
Steve Kratz at Department of Community and Economic Development, and Nadine Späth at Pennsylvania’s Authorized Trade Representative explain why, and what sets Pennsylvania apart from the rest.
For a small country, the Netherlands is definitely not a small player in life sciences and health. The Dutch sector owes its position to a strong foundation of excellent science, a vast clinical research infrastructure, and a culture of entrepreneurship and open innovation. Sandra Migchielsen at Amsterdam Innovation Motor provides an insight into the successfully hosted BIO-Europe Spring® 2012.
Vicki Salmon at IP asset LLP questions whether the system that is being proposed makes life easier or more difficult for technology companies, whether the political deal is a good one, and how, if it comes about, it should affect your current patenting and business strategies.
Bart Laenen at LC Patents discusses the appraisal of non-governmental organisations objecting to the practice of the EPO in awarding patents to companies.
